INTRODUCTION: @entity8142 agonists ( @entity6757 RAs) are increasingly being used for treatment for @entity6 , but consideration of benefits and potential adverse events is required. This review examines the state of glycemic control, @entity353 , blood pressure, and tolerability, as well as the current debate about the safety of @entity6757 RAs, including risk of @entity788 , @entity788 , and @entity259 . METHODS: A MEDLINE search (2010-2015) identified publications that discussed longer-acting @entity6757 RAs. Search terms included @entity8142 agonists, liraglutide, exenatide, lixisenatide, @entity69217 , @entity48142 , albiglutide, efficacy, safety, @entity788 , @entity788 , and @entity259 . Abstracts from the American @entity6 Association, European Association for the Study of @entity6 , and American Association of Clinical Endocrinologists from 2010 to 2015 were also searched. Efficacy and safety studies, pooled analyses, and meta-analyses were prioritized. RESULTS: Research has confirmed @entity6757 RAs provide robust glycemic control, @entity353 , and blood pressure reduction. Current studies do not prove increased risk of @entity788 , @entity788 , or @entity259 but more trials are needed since publications that indicate safety or suggest increased risk have methodological flaws that prevent firm conclusions to be drawn about these rare, long-term events. CONCLUSION: @entity6757 RA therapy in the context of individualized, @entity1 -centered care continues to be supported by current literature. @entity6757 RA therapy provides robust glycemic control, blood pressure reduction, and @entity353 , but studies are still needed to address concerns about tolerability and safety, including @entity788 and @entity5 .

@entity8142 Agonists for Type 2 XXXX : A Clinical Update of Safety and Efficacy.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis', 'pancreatic cancer'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'type 2 diabetes mellitus'] @entity69217 :: ('MESH:C000591245', 'Chemical') :: ['semaglutide'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity6757 :: ('100125288', 'Gene') :: ['GLP-1'] @entity8142 :: ('2740', 'Gene') :: ['GLP-1 receptor', 'Glucagon-like peptide-1 receptor'] @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid cancer'] @entity48142 :: ('MESH:C555680', 'Chemical') :: ['dulaglutide']
@entity6 :: (MESH:D003920,Disease) :: ['Diabetes']
